SHR ‐2004, a Humanized Monoclonal Antibody Targeting Factor XI , for Preventing Venous Thromboembolism After Ovarian Cancer Surgery: A Randomized, Active‐Controlled Phase 2 Study
- 26 August 2026
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 101 (11) , 2776-2785
Abstract
This multicenter, randomized, open‐label, exploratory Phase 2 trial assessed SHR‐2004, an anti‐FXI antibody, for venous thromboembolism (VTE) prevention in patients undergoing ovarian cancer surgery—a population at particularly high thrombotic risk conducted at 25 sites in China. Patients with newly diagnosed Stage III–IV or recurrent ovarian cancer scheduled for surgery were randomly assigned (1:1) to receive subcutaneous SHR‐2004 (180 mg on Day 1 and 120 mg on Day 15) or enoxaparin–rivaroxaban (subcutaneous enoxaparin 40 mg once daily during hospitalization, followed by oral rivaroxaban 10 mg once daily after discharge until Day 28). The primary efficacy outcome was the composite of VTE events within 28 days. The primary safety outcome was major bleeding (MB) or clinically relevant nonmajor bleeding (CRNMB) from first dose to 28 days. Between February 19, 2024 and September 17, 2024, 198 patients received assigned treatment (90 with SHR‐2004, 108 with enoxaparin–rivaroxaban) and were included in the safety analysis. Among 181 patients who completed protocol‐mandated ultrasonography, VTE occurred in 11 (12.6%) patients in the SHR‐2004 group and 19 (20.2%) in the enoxaparin–rivaroxaban group (difference −8.4%, 95% CI −19.9 to 3.1) by Day 28. MB/CRNMB rates were similar between groups (SHR‐2004: 2/90 [2.2%]; enoxaparin–rivaroxaban: 2/108 [1.9%]). In this study, SHR‐2004 showed comparable efficacy to enoxaparin–rivaroxaban for preventing postoperative VTE in patients undergoing ovarian cancer surgery, with a similar low risk of MB or CRNMB. The twice‐monthly dosing schedule offers a potential advantage over daily anticoagulation, supporting further investigation in adequately powered Phase 3 trials. Trial Registration: ClinicalTrials.gov identifier: NCT06220123Keywords
This publication has 21 references indexed in Scilit:
- New horizons in the pharmacological management of venous thromboembolismHemaSphere, 2025
- The first-in-human study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the factor XI monoclonal antibody SHR-2004 in healthy subjectsExpert Opinion on Investigational Drugs, 2024
- Risk of Venous Thromboembolic Events After Surgery for CancerJAMA Network Open, 2024
- BJTJ-1837, a novel FXI activation-blocking antibodyResearch and Practice in Thrombosis and Haemostasis, 2023
- Antithrombotic Therapy for VTE DiseaseChest, 2021
- Factor XI Inhibition to Uncouple Thrombosis From HemostasisJACC, 2021
- Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant NeoplasmJAMA Network Open, 2020
- Venous thromboembolism in ovarian cancer: incidence, risk factors and impact on survivalEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2013
- Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patientsCancer, 2007
- Malignancies, Prothrombotic Mutations, and the Risk of Venous ThrombosisJAMA, 2005